BenevolentAI: Leadership Team Change
July 03 2024 - 1:00AM
Business Wire
Regulatory News:
BenevolentAI (“BenevolentAI” or the “Company”) (Euronext
Amsterdam: BAI), a leader in applying advanced artificial
intelligence (AI) to accelerate biopharma drug discovery, today
announces a change to its Executive Leadership Team (ELT) following
the recent Annual General Meeting and the election of a new Board
of Directors.
In a move to better enhance operational efficiency and strategic
focus, the Board initiated a leadership review to better support
BenevolentAI's ambitious growth plans. The results of the review
include Ms. Catherine Isted stepping down from her role as Chief
Financial Officer. The Board extends its gratitude to Ms. Isted for
her contributions. Mr. Tom Holgate, who has been at BenevolentAI
for nearly seven years, will continue in his role as Group Finance
Director, ensuring continuity and leveraging his extensive
understanding of the Company's financial landscape to lead several
pivotal financial initiatives.
The Company is intensifying its efforts to capitalise on the
expanding opportunities within the rapidly maturing 'techbio'
sector. BenevolentAI's strong momentum is underscored by last
week’s successful integration of a novel target in Systemic Lupus
Erythematosus into AstraZeneca's portfolio, marking yet another
significant milestone for the Company and the second major
collaboration milestone achieved with AstraZeneca this year.
The Board's review further highlighted the need to adopt a more
dynamic and entrepreneurial approach across the Company’s
leadership, business development activities, and internal
management structures. These changes are designed to expand the
Company's market share in the AI-driven drug discovery sector,
accelerate the development of its internal pipelines, and forge new
strategic collaborations.
Dr Joerg Moeller, Chief Executive Officer of BenevolentAI,
commented: “It has been a pleasure to work alongside Catherine
and I would like to thank her for her contribution and commitment
during her time as Chief Financial Officer. As a leader in applying
advanced AI to accelerate biopharma drug discovery, at
BenevolentAI, we remain focused on delivering value creation for
all our shareholders and delivering innovative medicines to
patients suffering from serious medical conditions.”
PUBLIC DISCLOSURE OF INSIDE INFORMATION IN ACCORDANCE WITH
ARTICLE 17(1) OF THE REGULATION (EU) NO 596/2014 ON MARKET ABUSE
(MARKET ABUSE REGULATION).
About BenevolentAI
At BenevolentAI (AMS: BAI), we serve patients by leveraging our
proprietary and validated Benevolent Platform™ that integrates AI
and science to uncover new biology, predict novel targets and
develop first-in-class or best-in-class drugs for complex diseases.
By applying proprietary advanced AI tools, in combination with
in-house scientific expertise and wet-lab facilities, BenevolentAI
is well-positioned to identify and accelerate novel drug
discovery.
The Company’s business model presents multiple routes for value
creation including discovery collaborations with pharma companies
like AstraZeneca and Merck and advancing in-house pipelines to
inflection points. Headquartered in London, with wet labs in
Cambridge (UK), BenevolentAI is at the forefront of reshaping the
future of drug discovery and delivering innovative medicines.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240702782787/en/
Enquiries:
Investors: Dr. Joerg Moeller – Chief Executive
Officer investors@benevolent.ai T: +44 (0) 203 781 9360
Media: James Osborn – Communications Lead
press@benevolent.ai T: +44 (0) 203 781 9360
FTI Consulting: Ben Atwell / Simon Conway / Victoria
Foster Mitchell BenevolentAI@fticonsulting.com T: +44 (0) 203 727
1000